Bluejay Diagnostics reports SYMON-II data: 777 patients, 18% 28-day mortality

Bluejay Diagnostics announced baseline SYMON-II data that included 777 evaluable patients and an approximately 18% 28-day mortality rate to support IL-6 prognostic evaluation.